"ID","FLDNAME","TBLNAME","CRFNAME","QUESTION","TEXT","STATUS","DEPRULE","TYPE","LENGTH","DECIML","RANGEVAL","RANGESQL","RANGEPRL","UNITS","CODE","NOTES","OBJID","COLID","RANGEJSCPT","NAVJSCPT","FTYPE","TAB","DE","MC","VISIBLE","LOGVISIBLE","MTBLNAME","SUBTBLNAME","POPJSCPT","GRID","DEF","update_stamp"
"-4","RID","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","Participant roster ID","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","The 4 digit roster ID (RID) should be used to merge data","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VISCODE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","Visit code","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VISCODE2","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","Translated visit code","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","Months from baseline rounded to nearest 6 months","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","EXAMDATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","Examination Date","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","SAMPLEID","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLOBAL.SPEC.ID","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","EDTA_PLASMA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Detected EDTA anticoagulant. This indicates a EDTA plasma sample. EDTA anticoagulant interferes with the quantification of glycerol, glycine and pyruvate. Also, metabolites may behave differently (mainly in absolute concentration terms, but potentially also in association terms) in serum and EDTA plasma due to the different biological matrices.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","CITRATE_PLASMA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","A non-physiological citrate concentration. This may result from the sample being citrate plasma.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LOW_ETHANOL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","This arises potentially due to disinfectant contaminations in the blood donation/collection process and/or contamination in air from lab handling, such as cleaning of well-plates. In higher concentrations, ethanol prohibits the quantification of glycerol, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of glycerol and result in artificially distorted glycerol levels. We recommend caution when interpreting absolute glycerol concentrations. It is also good to note that high alcohol in the sample might artificially increase the acetate concentration.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","MEDIUM_ETHANOL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","This arises potentially due to disinfectant contaminations in the blood donation/collection process and/or contamination in air from lab handling, such as cleaning of well-plates. In higher concentrations, ethanol prohibits the quantification of glycerol and 3-hydroxybutyrate, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of glycerol and 3-hydroxybutyrate and result in artificially distorted glycerol and 3-hydroxybutyrate levels. We recommend caution when interpreting absolute glycerol and 3-hydroxybutyrate concentrations. It is also good to note that high alcohol in the sample might artificially increase the acetate concentration.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HIGH_ETHANOL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","This arises potentially due to disinfectant contaminations in the blood donation/collection process and/or contamination in air from lab handling, such as cleaning of well-plates. In higher concentrations, ethanol prohibits the quantification of glycerol, 3-hydroxybutyrate and valine, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of glycerol, 3-hydroxybutyrate and valine and result in artificially distorted glycerol, 3-hydroxybutyrate and valine levels. We recommend caution when interpreting absolute glycerol, 3-hydroxybutyrate and valine concentrations. It is also good to note that high alcohol in the sample might artificially increase the acetate concentration.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ISOPROPYL_ALCOHOL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Isopropyl alcohol signals detected. In higher concentrations, this compound prohibits the quantification of creatinine, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of creatinine and result in artificially distorted creatinine levels. We recommend caution when interpreting absolute creatinine concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","N_METHYL_2_PYRROLIDONE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","A compound that can be used in sample collection processes. In higher concentrations, it prohibits the quantification of glutamine, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of glutamine and result in artificially distorted glutamine levels. We recommend caution when interpreting absolute glutamine concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","POLYSACCHARIDES","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Polysaccharide or some other type of carbohydrate signals detected. Most commonly observed along with other signs of suboptimal sample quality, but may also indicate presence of heparin. In higher concentrations, this compound prohibits the quantification of creatinine, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of creatinine and result in artificially distorted creatinine levels. We recommend caution when interpreting absolute creatinine concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","AMINOCAPROIC_ACID","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Aminocaproic acid detected in the sample; this compound is an antifibrinolytic agent. In higher concentrations, it prohibits the quantification of acetone, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LOW_GLUCOSE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HIGH_LACTATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HIGH_PYRUVATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LOW_GLUTAMINE_OR_HIGH_GLUTAMATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","In these samples most of the glutamine appears to have degraded into glutamate. This can take place, e.g. during the sample collection process, if the sample is kept at room temperature for a prolonged period of time, there are multiple freeze-thaw cycles, or there are oxidative conditions / oxidation occurs in the sample. In these samples glutamine is not quantified. In higher concentrations, glutamate prohibits the quantification of pyruvate, and therefore the sample has been flagged with a ""TAG"", and no concentration has been provided for the sample. In lower concentrations, glutamate may interfere with the reliable quantification of pyruvate and result in artificially distorted pyruvate levels. We recommend caution when interpreting absolute pyruvate concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLUCONOLACTONE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Gluconolactone is an oxidation product of glucose and is not normally detected in samples. Interferes with the quantification of creatinine.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LOW_PROTEIN","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Unexpected protein features have been identified during the analysis. This quality observation is related to unexpectedly low total protein concentration in the sample and may be an indication of potential sample dilution. Sample dilution may occur due to water contamination, or prolonged storage in freezer in combination with loosely closed tube caps, which exposes the sample to collect ice and increases the chances of dilution.
In case there is reason to assume sample dilution, we recommend caution when analyzing absolute concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNEXPECTED_AMINO_ACID_SIGNALS","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","These are signals that we do not typically observe in normal samples. It is likely that they relate to protein breakage due to non optimal storage.
Interferes with the reliable quantification of citrate and glycerol, and may result in artificially distorted metabolite concentrations.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNIDENTIFIED_MACROMOLECULES","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Signals from abnormal macromolecule(s)/protein(s).
Interferes with the quantification of phenylalanine, acetate, acetone, glutamine and pyruvate.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNIDENTIFIED_SMALL_MOLECULE_A","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Untypical signals from unknown small molecule(s); potentially xenobiotics.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNIDENTIFIED_SMALL_MOLECULE_B","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Untypical signals from unknown small molecule(s); potentially xenobiotics. Interferes with the quantification of acetate.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNIDENTIFIED_SMALL_MOLECULE_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Unidentified signals at 2.27 ppm and various other spectral areas. Interferes with the reliable quantification of albumin, creatinine, glycerol, glycine and acetone.","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","BELOW_LIMIT_OF_QUANTIFICATION","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Below Limit-Of-Quantification (LOQ) means that the concentration of the given biomarker is smaller than the range where the Nightingale platform offers highly accurate quantification. For instance, the LOQ for lipoprotein lipid measures is < 0.01 mmol/L. The estimated biomarker concentration is reported for use in certain epidemiological analyses, but it may be advisable to conduct sensitivity analyses with all values below LOQ excluded.
","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","NON_HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total cholesterol minus HDL-C","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","REMNANT_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Remnant cholesterol (non-HDL, non-LDL -cholesterol)","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","VLDL cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","CLINICAL_LDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Clinical LDL cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","LDL cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","HDL cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total triglycerides","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Triglycerides","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Triglycerides","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Triglycerides","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Triglycerides","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total phospholipids in lipoprotein particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Phospholipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Phospholipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Phospholipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Phospholipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total esterified cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesteryl esters","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesteryl esters","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesteryl esters","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Cholesteryl esters","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total free cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Free cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Free cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Free cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Free cholesterol","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in lipoprotein particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Total lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Total lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Total lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Total lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total concentration of lipoprotein particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein particle concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein particle concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of LDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein particle concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein particle concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VLDL_SIZE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Average diameter for VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","nm","-4","Lipoprotein particle sizes","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LDL_SIZE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Average diameter for LDL particles","-4","-4","-4","-4","-4","-4","-4","-4","nm","-4","Lipoprotein particle sizes","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HDL_SIZE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Average diameter for HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","nm","-4","Lipoprotein particle sizes","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PHOSPHOGLYC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phosphoglycerides","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Other lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TG_BY_PG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of triglycerides to phosphoglycerides","-4","-4","-4","-4","-4","-4","-4","-4","ratio","-4","Other lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","CHOLINES","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total cholines","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Other lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PHOSPHATIDYLC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phosphatidylcholines","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Other lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","SPHINGOMYELINS","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Sphingomyelins","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Other lipids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","APOB","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Apolipoprotein B","-4","-4","-4","-4","-4","-4","-4","-4","g/l","-4","Apolipoproteins","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","APOA1","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Apolipoprotein A1","-4","-4","-4","-4","-4","-4","-4","-4","g/l","-4","Apolipoproteins","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","APOB_BY_APOA1","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of apolipoprotein B to apolipoprotein A1","-4","-4","-4","-4","-4","-4","-4","-4","ratio","-4","Apolipoproteins","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_FA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","UNSATURATION","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Degree of unsaturation","-4","-4","-4","-4","-4","-4","-4","-4","degree","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","OMEGA_3","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Omega-3 fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","OMEGA_6","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Omega-6 fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PUFA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Polyunsaturated fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","MUFA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Monounsaturated fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","SFA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Saturated fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Linoleic acid","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","DHA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Docosahexaenoic acid","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","OMEGA_3_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of omega-3 fatty acids to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","OMEGA_6_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of omega-6 fatty acids to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PUFA_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of polyunsaturated fatty acids to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","MUFA_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of monounsaturated fatty acids to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","SFA_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of saturated fatty acids to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LA_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of linoleic acid to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","DHA_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of docosahexaenoic acid to total fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PUFA_BY_MUFA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of polyunsaturated fatty acids to monounsaturated fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","ratio","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","OMEGA_6_BY_OMEGA_3","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Ratio of omega-6 fatty acids to omega-3 fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","ratio","-4","Fatty acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ALA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Alanine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLN","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Glutamine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLY","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Glycine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","HIS","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Histidine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TOTAL_BCAA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total concentration of branched-chain amino acids (leucine + isoleucine + valine)","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ILE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Isoleucine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LEU","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Leucine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","VAL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Valine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PHE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phenylalanine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","TYR","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Tyrosine","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Amino acids","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLUCOSE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Glucose","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Glycolysis related metabolites","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","LACTATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Lactate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Glycolysis related metabolites","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","PYRUVATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Pyruvate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Glycolysis related metabolites","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","CITRATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Citrate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Glycolysis related metabolites","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLYCEROL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Glycerol","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Glycolysis related metabolites","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","BOHBUTYRATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","3-Hydroxybutyrate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Ketone bodies","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ACETATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Acetate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Ketone bodies","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ACETOACETATE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Acetoacetate","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Ketone bodies","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ACETONE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Acetone","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Ketone bodies","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","CREATININE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Creatinine","-4","-4","-4","-4","-4","-4","-4","-4","?mol/l","-4","Fluid balance","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","ALBUMIN","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Albumin","-4","-4","-4","-4","-4","-4","-4","-4","g/l","-4","Fluid balance","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","GLYCA","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Glycoprotein acetyls","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Inflammation","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of chylomicrons and extremely large VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of very large VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of large VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of medium VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of small VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of very small VLDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of IDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in IDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of large LDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of medium LDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of small LDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of very large HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of large HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of medium HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_P","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Concentration of small HDL particles","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_L","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Total lipids in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_PL","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_C","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_CE","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_FC","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_TG","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","mmol/l","-4","Lipoprotein subclasses","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XXL_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in very large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in large VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in medium VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XS_VLDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in very small VLDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in IDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in IDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in IDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in IDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","IDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in IDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_LDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in large LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_LDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in medium LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_LDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in small LDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","XL_HDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in very large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","L_HDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in large HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","M_HDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in medium HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_PL_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Phospholipids to total lipids ratio in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_C_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesterol to total lipids ratio in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_CE_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Cholesteryl esters to total lipids ratio in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_FC_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Free cholesterol to total lipids ratio in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"
"-4","S_HDL_TG_PCT","ADNINIGHTINGALE2","ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites ","","Triglycerides to total lipids ratio in small HDL","-4","-4","-4","-4","-4","-4","-4","-4","%","-4","Relative lipoprotein lipid concentrations","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","-4","2021-02-25 12:33:09.0"